Thursday 16 October, 2025
Objectives: Therapeutic drug monitoring (TMD) is increasingly advocated in clinical practice. Most of the time, target concentration windows are established…
Read morePoster: Clinical Applications
Individual virtual controls as surrogate for a control arm – application for siRNA and NA therapy in chronic hepatitis B infection
Thursday 16 October, 2025
Objectives: Clinical studies often include a control arm, either placebo or standard-of-care (SOC), to determine the (additional) effect of an investigational…
Read moreUsing microdose-based activity measurement to individualise dosing of cytochrome P450 metabolised drugs: a case study with yohimbine and tamoxifen
Thursday 16 October, 2025
Objectives: Understanding pharmacokinetic (PK) interindividual variability (IIV) can enable reaching optimal drug exposure, minimising therapeutic failure. Genotype-derived phenotypes are often…
Read moreA population pharmacokinetic and exposure-response model to support therapeutic drug monitoring during vedolizumab induction therapy
Thursday 16 October, 2025
Objectives: Vedolizumab (VDZ) is a monoclonal antibody used to treat patients with ulcerative colitis (UC) and Crohn’s disease (CD). Patients…
Read moreBuilding model-informed precision dosing software using R: blueprint for a state-of-the-art development process
Thursday 16 October, 2025
Objectives: Over the last few years, the pharmacometrics community showed a renewed interest in model-informed precision dosing (MIPD). Although a…
Read morePredictive model of postoperative nausea and vomiting in patients treated with Fentanyl-based intravenous patient controlled analgesia
Thursday 16 October, 2025
Introduction: Postoperative nausea and vomiting (PONV) is often ranked by patients as one of the most undesirable postoperative outcomes [1]….
Read moreModel-based dose optimization of ivermectin to achieve equivalent exposure coverage in children and adults
Thursday 16 October, 2025
Objectives: Soil-transmitted helminthiasis is a neglected tropical disease mostly affecting the poorest and most deprived communities in tropical and sub-tropical…
Read moreA model-based approach to predict SC administration and free target dynamics for monoclonal antibodies using PK and total target measurements after IV administration
Thursday 16 October, 2025
Introduction The non-linear pharmacokinetics (PK) of monoclonal antibodies (mAbs) can be characterized by target-mediated drug disposition (TMDD) models (1,2). However,…
Read moreA model-based approach to support a label update for flexible dosing of secukinumab in patients with plaque psoriasis
Thursday 16 October, 2025
Objectives: Secukinumab (Cosentyx®) is approved for the treatment of plaque psoriasis using a standard regimen of 300 mg Q4W administered…
Read morePopulation pharmacokinetic modelling and simulation of imeglimin in type 2 diabetes patients to support dose recommendations to patients with renal impairment
Thursday 16 October, 2025
Introduction: Imeglimin is a novel first-in class oral antidiabetic drug to treat type 2 diabetes (T2DM) [1]. Imeglimin is not…
Read more